Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and July 2017

Showing 1 to 10 of 338
Title Reference number Published Last updated
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) Reference number:TA452 TA00452 Published:July 2017 20170701 Last updated:July 2017 20170705
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) Reference number:TA453 TA00453 Published:July 2017 20170701 Last updated:July 2017 20170705
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) Reference number:TA454 TA00454 Published:July 2017 20170701 Last updated:July 2017 20170705
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma Reference number:TA446 TA00446 Published:June 2017 20170601 Last updated:June 2017 20170628
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer Reference number:TA447 TA00447 Published:June 2017 20170601 Last updated:June 2017 20170628
Etelcalcetide for treating secondary hyperparathyroidism Reference number:TA448 TA00448 Published:June 2017 20170601 Last updated:June 2017 20170628
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease Reference number:TA449 TA00449 Published:June 2017 20170601 Last updated:June 2017 20170628
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia Reference number:TA450 TA00450 Published:June 2017 20170601 Last updated:June 2017 20170628
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia Reference number:TA451 TA00451 Published:June 2017 20170601 Last updated:June 2017 20170628
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) Reference number:TA444 TA00444 Published:May 2017 20170501 Last updated:May 2017 20170524